Mezavant

Array
(
    [ID] => 10885
    [post_author] => 8
    [post_date] => 2014-12-15 19:04:46
    [post_date_gmt] => 2014-12-15 22:04:46
    [post_content] => 
Forma farmacéutica
Comprimidos de Liberación Prolongada Gastrorresistentes
Composición
Cada Comprimido de Liberación Prolongada Gastrorresistente contiene:
Mezalazina 1200 mg
Acción terapéutica
Agente antiinflamatorio intestinal del grupo ácido aminosalicílico y similares. Actúa en toda la zona del colon y recto mediante el tratamiento de la inflamación y la reducción de los síntomas de la colitis ulcerosa.
Indicaciones
Mezavant está indicado para inducir la remisión endoscópica y clínica en pacientes con colitis ulcerosa activa de leve a moderada; así como para el mantenimiento de la remisión.
Presentaciones
Envases conteniendo 30 y 60 comprimidos.

 
    [post_title] => Mezavant
    [post_excerpt] => Agente antiinflamatorio intestinal del grupo ácido aminosalicílico y similares
    [post_status] => publish
    [comment_status] => closed
    [ping_status] => closed
    [post_password] => 
    [post_name] => mezavant-2
    [to_ping] => 
    [pinged] => 
    [post_modified] => 2021-09-07 10:38:24
    [post_modified_gmt] => 2021-09-07 13:38:24
    [post_content_filtered] => 
    [post_parent] => 0
    [guid] => https://www.bago.com.ar/vademecum/?post_type=productos&p=10885
    [menu_order] => 0
    [post_type] => productos
    [post_mime_type] => 
    [comment_count] => 0
    [filter] => raw
    [prospecto_para_pacientes] => Array
        (
        )

    [url_para_mayor_informacion_video] => 
    [url_para_mayor_informacion] => 
    [url_productos_consumo_masivo] => 
    [prospecto] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 11869
                    [post_author] => 16
                    [post_date] => 2015-09-07 13:40:07
                    [post_date_gmt] => 2015-09-07 16:40:07
                    [post_content] => 
                    [post_title] => Prospecto Mezavant
                    [post_excerpt] => 
                    [post_status] => inherit
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => prospecto-mezavant
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2015-09-07 13:40:07
                    [post_modified_gmt] => 2015-09-07 16:40:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://www.bago.com.ar/vademecum/wp-content/uploads/2015/09/Prospecto-Mezavant.pdf
                    [menu_order] => 0
                    [post_type] => attachment
                    [post_mime_type] => application/pdf
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [presentacion_img] => Array
        (
        )

    [logo_img] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 11126
                    [post_author] => 16
                    [post_date] => 2015-02-12 16:59:20
                    [post_date_gmt] => 2015-02-12 16:59:20
                    [post_content] => 
                    [post_title] => logo_lanzamiento_mezavant.jpg
                    [post_excerpt] => 
                    [post_status] => inherit
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => logo_lanzamiento_mezavant-jpg-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2015-02-12 16:59:20
                    [post_modified_gmt] => 2015-02-12 16:59:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://www.bago.com.ar/vademecum/?attachment_id=11126
                    [menu_order] => 0
                    [post_type] => attachment
                    [post_mime_type] => image/jpeg
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [foto_producto] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 19076
                    [post_author] => 17
                    [post_date] => 2021-09-07 10:37:54
                    [post_date_gmt] => 2021-09-07 13:37:54
                    [post_content] => 
                    [post_title] => banner-mezavant
                    [post_excerpt] => 
                    [post_status] => inherit
                    [comment_status] => open
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => banner-mezavant
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-09-07 10:37:54
                    [post_modified_gmt] => 2021-09-07 13:37:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://www.bago.com.ar/vademecum/wp-content/uploads/2021/09/banner-mezavant.jpg
                    [menu_order] => 0
                    [post_type] => attachment
                    [post_mime_type] => image/jpeg
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [fotos_lanzamiento] => Array
        (
        )

    [especialidad] => Array
        (
        )

    [marca] => Array
        (
            [0] => Mezavant
        )

    [principio_activo] => Array
        (
            [0] => Mezalazina
        )

    [post_content_formatted] => 
Forma farmacéutica
Comprimidos de Liberación Prolongada Gastrorresistentes
Composición
Cada Comprimido de Liberación Prolongada Gastrorresistente contiene:

Mezalazina 1200 mg
Acción terapéutica
Agente antiinflamatorio intestinal del grupo ácido aminosalicílico y similares. Actúa en toda la zona del colon y recto mediante el tratamiento de la inflamación y la reducción de los síntomas de la colitis ulcerosa.
Indicaciones
Mezavant está indicado para inducir la remisión endoscópica y clínica en pacientes con colitis ulcerosa activa de leve a moderada; así como para el mantenimiento de la remisión.
Presentaciones
Envases conteniendo 30 y 60 comprimidos.
 

)

Array
(
    [_wp_attached_file] => Array
        (
            [0] => prospectos/Prospecto-Mezavant.pdf
        )

)

anexo_congre_single